Preliminary results show that a combined test for mutation of FGFR3, PIK3CA and RAS could potentially detect 75% of primary tumours, including 88% of the pTa-T1G1-2 tumours but only 36% of the high-grade and -stage malignancies [79]. This evidence concerns the gene PIK3CA and neoplasm.